Detailed view for LmjF.25.0960
Basic information
TDR Targets ID: 23078
Leishmania major, gamma-tubulin
Source Database / ID: TriTrypDB GeneDB
Leishmania major, gamma-tubulin
Source Database / ID: TriTrypDB GeneDB
pI: 6.3855 |
Length (AA): 447 |
MW (Da): 50031 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Network
Gene Ontology
Mouse over links to read term descriptions.
GO:0000930
gamma-tubulin complex GO:0031122 cytoplasmic microtubule organization and biogenesis
GO:0007020 microtubule nucleation
GO:0005874 microtubule
GO:0043234 protein complex
GO:0005525 GTP binding
GO:0003924 GTPase activity
GO:0051258 protein polymerization
GO:0007017 microtubule-based process
Metabolic Pathways
This gene is not mapped to any metabolic pathway in KEGG.
Structural information
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
| Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
|---|---|---|---|---|---|---|---|---|---|
| 2 | 440 | 1z5v (A) | 2 | 440 | 67.00 | 0 | 1 | 1.82 | -1.56 |
| 3 | 441 | 1sa0 (B) | 2 | 438 | 34.00 | 0 | 1 | 1.47 | -1.61 |
| 3 | 438 | 1sa0 (A) | 2 | 435 | 33.00 | 0 | 1 | 1.5 | -1.64 |
| 2 | 444 | 3cb2 (A) | 2 | 444 | 67.00 | 0 | 1 | 1.88565 | -1.64 |
Help me make sense of these data.
Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
No structure availble in the PDB for this protein
Expression
| Upregulation Percent | Ranking | Stage | Dataset |
|---|---|---|---|
| Upper 60-80% percentile | amastigotes, metacyclic. | Fernandes MC |
-
Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.
Orthologs
Ortholog group members (OG5_127652)
| Species | Accession | Gene Product |
|---|---|---|
| Arabidopsis thaliana | AT5G05620 | tubulin gamma-2 chain |
| Arabidopsis thaliana | AT3G61650 | tubulin gamma-1 chain |
| Babesia bovis | BBOV_IV007250 | tubulin gamma chain |
| Brugia malayi | Bm1_55245 | Tubulin gamma chain |
| Candida albicans | CaO19.8823 | gamma tubulin-like protein |
| Candida albicans | CaO19.1238 | gamma tubulin-like protein |
| Caenorhabditis elegans | CELE_F58A4.8 | Protein TBG-1 |
| Cryptosporidium hominis | Chro.70228 | gamma-tubulin |
| Cryptosporidium parvum | cgd7_1980 | gamma tubulin |
| Dictyostelium discoideum | DDB_G0271738 | gamma tubulin |
| Drosophila melanogaster | Dmel_CG17566 | gamma-Tubulin at 37C |
| Drosophila melanogaster | Dmel_CG3157 | gamma-Tubulin at 23C |
| Echinococcus granulosus | EgrG_001099700 | tubulin gamma 1 chain |
| Entamoeba histolytica | EHI_008240 | tubulin gamma chain |
| Echinococcus multilocularis | EmuJ_001099700 | tubulin gamma 1 chain |
| Giardia lamblia | GL50803_114218 | Gamma tubulin |
| Homo sapiens | ENSG00000131462 | tubulin, gamma 1 |
| Homo sapiens | ENSG00000037042 | tubulin, gamma 2 |
| Leishmania braziliensis | LbrM.25.0840 | gamma-tubulin |
| Leishmania donovani | LdBPK_250990.1 | tubulin gamma chain |
| Leishmania infantum | LinJ.25.0990 | gamma-tubulin |
| Leishmania major | LmjF.25.0960 | gamma-tubulin |
| Leishmania mexicana | LmxM.25.0960 | gamma-tubulin |
| Loa Loa (eye worm) | LOAG_02400 | tubulin gamma chain |
| Mus musculus | ENSMUSG00000045007 | tubulin, gamma 2 |
| Mus musculus | ENSMUSG00000035198 | tubulin, gamma 1 |
| Neospora caninum | NCLIV_046130 | Beta-tubulin, related |
| Oryza sativa | 4337861 | Os05g0156600 |
| Plasmodium berghei | PBANKA_1226600 | tubulin gamma chain, putative |
| Plasmodium falciparum | PF3D7_0803700 | tubulin gamma chain |
| Plasmodium knowlesi | PKNH_0115200 | tubulin gamma chain, putative |
| Plasmodium vivax | PVX_093560 | tubulin gamma chain, putative |
| Plasmodium yoelii | PY00808 | tubulin gamma chain |
| Saccharomyces cerevisiae | YLR212C | Tub4p |
| Schistosoma japonicum | Sjp_0036720 | ko:K10389 tubulin gamma, putative |
| Schistosoma mansoni | Smp_034670 | tubulin subunit gamma |
| Schmidtea mediterranea | mk4.005127.01 | Tubulin gamma chain |
| Schmidtea mediterranea | mk4.005127.02 | Tubulin gamma chain |
| Schmidtea mediterranea | mk4.005127.00 | Tubulin gamma chain |
| Schmidtea mediterranea | mk4.006572.00 | Tubulin gamma chain |
| Trypanosoma brucei gambiense | Tbg972.3.550 | gamma tubulin |
| Trypanosoma brucei | Tb927.3.910 | tubulin gamma chain |
| Trypanosoma congolense | TcIL3000_0_03350 | tubulin gamma chain |
| Trypanosoma cruzi | TcCLB.511867.190 | tubulin gamma chain |
| Theileria parva | TP03_0233 | tubulin gamma chain, putative |
| Trichomonas vaginalis | TVAG_109820 | tubulin gamma chain, putative |
| Trichomonas vaginalis | TVAG_369500 | tubulin, putative |
Essentiality
LmjF.25.0960 has one or more orthologs with essentiality data
| Gene/Ortholog | Organism | Phenotype | Source Study |
|---|---|---|---|
| Tb927.3.910 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
| Tb927.3.910 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
| Tb927.3.910 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
| Tb927.3.910 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
| CELE_F58A4.8 | Caenorhabditis elegans | embryonic lethal | wormbase |
| CELE_F58A4.8 | Caenorhabditis elegans | sterile | wormbase |
| YLR212C | Saccharomyces cerevisiae | inviable | yeastgenome |
-
shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan -
neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs -
blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930 -
alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924 -
yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database -
keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection -
nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource -
wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170 -
gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
Phenotypes and Validation (curated)
Annotated phenotypes:
| Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
|---|---|---|---|---|---|---|
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 09/08/82. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; . | References: | 2392684 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 09/08/82. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; . | References: | 2392684 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | 79195 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 2044859 | |
| morphology (PATO:0000051) | abnormal (PATO:0000460) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from visible phenotype (ECO:0000176) | Leishmania mexicana | 79195 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 2044859 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | 79195 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 2044859 | |
| cell differentiation (GO:0030154) | disrupted (PATO:0001507) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | 79195 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with antimicrotubule agents leads to disrupted differentiation from promastigote to amastigote of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 2044859 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | 586034 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 95480-32-3. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 8468004 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | 13316 39854 79195 544264 551075 552236 554547 555991 557331 559236 559237 559604 561797 562909 564379 564831 568817 568820 568821 569525 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 29091-21-2. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 7818612 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania major | 39854 250338 536202 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 121-50-6; Drug: 394-25-2; Drug: 14371-82-5; Drug: 22227-59-4; Drug: 174824-16-9; Drug: 176177-41-6. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 8849257 | |
| microtubule polymerization (GO:0046785) | decreased (PATO:0000468) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from specific protein inhibition (ECO:0000020) | Leishmania amazonensis | 2976 8265 27599 67873 86876 250338 327961 371083 376038 543486 543487 559148 560712 572272 575226 588233 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 16037-91-5. chemical inhibition with antimicrotubule agents prevents mictotubule formation in vitro with purified tubulin and in live cells; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 10029309 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | 2976 8265 27599 67873 86876 250338 327961 371083 376038 543486 543487 559148 560712 572272 575226 588233 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 16037-91-5. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 10029309 | |
| microtubule polymerization (GO:0046785) | increased (PATO:0000470) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 2976 8265 559148 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with microtubule stabilising agent forces mictotubule formation in live cells and interrupts cell cycle; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 10427726 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 2976 8265 559148 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with microtubule stabilising agent forces mictotubule formation in live cells and interrupts cell cycle; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 10427726 | |
| growth (GO:0040007) | drug insensitive (PATO:0000528) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 2976 8265 559148 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with microtubule stabilising agent generated cell line resistant to drug with a MDR phenotype; reversible with Ca2+-channel blocker verapamil; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 10427727 | |
| growth (GO:0040007) | drug insensitive (PATO:0000528) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania infantum | 37094 39854 79195 250338 551075 562909 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 10546848 | |
| microtubule polymerization (GO:0046785) | decreased (PATO:0000468) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from specific protein inhibition (ECO:0000020) | Leishmania donovani | 2976 8265 80107 559148 576689 576690 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 11071278 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 2976 8265 80107 559148 576689 576690 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 11071278 | |
| cytokinesis (GO:0000910) | discontinuous (PATO:0000690) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from visible phenotype (ECO:0000176) | Leishmania donovani | 2976 8265 80107 559148 576689 576690 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 11071278 | |
| mitotic sister chromatid segregation (GO:0000070) | discontinuous (PATO:0000690) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from visible phenotype (ECO:0000176) | Leishmania donovani | 2976 8265 80107 559148 576689 576690 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 11071278 | |
| organelle localization (GO:0051640) | discontinuous (PATO:0000690) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from visible phenotype (ECO:0000176) | Leishmania donovani | 2976 8265 80107 559148 576689 576690 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 11071278 | |
| morphology (PATO:0000051) | abnormal (PATO:0000460) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from visible phenotype (ECO:0000176) | Leishmania donovani | 2976 8265 80107 559148 576689 576690 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 313705-89-4; Drug: 157207-90-4. chemical inhibition with antimicrotubule agents leads to abnormal cell morphology, cell division, mitosis, organelle localization & organization, and slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 11071278 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 12596 13316 15907 26907 78691 79195 527824 528258 531885 531886 532164 532165 532166 532195 532196 532197 532198 532199 532642 532643 532644 536969 536970 544264 552236 554547 559604 561797 564379 568817 568820 568821 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 10228-56-5; Drug: 36317-95-0; Drug: 62409-47-6; Drug: 62745-74-8; Drug: 204634-79-7; Drug: 483279-40-9; Drug: 483279-41-0; Drug: 483279-42-1; Drug: 483279-43-2; Drug: 483279-44-3; Drug: 483279-45-4; Drug: 483279-46-5; Drug: 483279-47-6; Drug: 88-91-5; Drug: 107-10-8; Drug: 1930-72-9; Drug: 97-08-5; Drug: 97-09-6; Drug: 62443-96-3; Drug: 483279-33-0; Drug: 483279-34-1; Drug: 483279-35-2; Drug: 483279-36-3; Drug: 483279-37-4; Drug: 483279-38-5; Drug: 483279-39-6. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 12161141 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 12596 13316 15907 26907 78691 79195 527824 528258 531885 531886 532164 532165 532166 532195 532196 532197 532198 532199 532642 532643 532644 536969 536970 544264 552236 554547 559604 561797 564379 568817 568820 568821 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 10228-56-5; Drug: 36317-95-0; Drug: 62409-47-6; Drug: 62745-74-8; Drug: 204634-79-7; Drug: 483279-40-9; Drug: 483279-41-0; Drug: 483279-42-1; Drug: 483279-43-2; Drug: 483279-44-3; Drug: 483279-45-4; Drug: 483279-46-5; Drug: 483279-47-6; Drug: 88-91-5; Drug: 107-10-8; Drug: 1930-72-9; Drug: 97-08-5; Drug: 97-09-6; Drug: 62443-96-3; Drug: 483279-33-0; Drug: 483279-34-1; Drug: 483279-35-2; Drug: 483279-36-3; Drug: 483279-37-4; Drug: 483279-38-5; Drug: 483279-39-6. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 12161141 | |
| microtubule polymerization (GO:0046785) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania donovani | 12596 13316 15907 26907 78691 79195 527824 528258 531885 531886 532164 532165 532166 532195 532196 532197 532198 532199 532642 532643 532644 536969 536970 544264 552236 554547 559604 561797 564379 568817 568820 568821 | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 10228-56-5; Drug: 36317-95-0; Drug: 62409-47-6; Drug: 62745-74-8; Drug: 204634-79-7; Drug: 483279-40-9; Drug: 483279-41-0; Drug: 483279-42-1; Drug: 483279-43-2; Drug: 483279-44-3; Drug: 483279-45-4; Drug: 483279-46-5; Drug: 483279-47-6; Drug: 88-91-5; Drug: 107-10-8; Drug: 1930-72-9; Drug: 97-08-5; Drug: 97-09-6; Drug: 62443-96-3; Drug: 483279-33-0; Drug: 483279-34-1; Drug: 483279-35-2; Drug: 483279-36-3; Drug: 483279-37-4; Drug: 483279-38-5; Drug: 483279-39-6. chemical inhibition with antimicrotubule agents prevents mictotubule formation in vitro with purified tubulin; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 12161141 | |
| cell cycle arrest (GO:0007050) | abnormal (PATO:0000460) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 79195 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 483279-40-9; Drug: 483279-44-3. chemical inhibition with antimicrotubule agents leads to cell cycle arrest in cell assay; unclear as to which topoisomerase II gene/enzyme was studied. | References: | 14645662 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 79195 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 19044-89-4; Drug: 19044-94-1; Drug: 483279-44-3; Drug: 483279-45-4; Drug: 619267-13-9; Drug: 619267-14-0; Drug: 619267-15-1; Drug: 619267-16-2; Drug: 619267-17-3; Drug: 619267-18-4; Drug: 619267-19-5; Drug: 619267-20-8; Drug: 619267-21-9; Drug: 619267-22-0; Drug: 619267-23-1; Drug: 619267-24-2; Drug: 619267-25-3; Drug: 619267-26-4; Drug: 678187-02-5; Drug: 678187-03-6; Drug: 678187-04-7; Drug: 678187-05-8; Drug: 678187-06-9; Drug: 678187-07-0; Drug: 678187-08-1; Drug: 678187-09-2; Drug: 678187-10-5; Drug: 678187-11-6; Drug: 678187-12-7; Drug: 678187-13-8; Drug: 678187-14-9. chemical inhibition with antimicrotubule agents leads to cell cycle arrest in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 15027874 | |
| microtubule polymerization (GO:0046785) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania donovani | 79195 | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 19044-89-4; Drug: 19044-94-1; Drug: 483279-44-3; Drug: 483279-45-4; Drug: 619267-13-9; Drug: 619267-14-0; Drug: 619267-15-1; Drug: 619267-16-2; Drug: 619267-17-3; Drug: 619267-18-4; Drug: 619267-19-5; Drug: 619267-20-8; Drug: 619267-21-9; Drug: 619267-22-0; Drug: 619267-23-1; Drug: 619267-24-2; Drug: 619267-25-3; Drug: 619267-26-4; Drug: 678187-02-5; Drug: 678187-03-6; Drug: 678187-04-7; Drug: 678187-05-8; Drug: 678187-06-9; Drug: 678187-07-0; Drug: 678187-08-1; Drug: 678187-09-2; Drug: 678187-10-5; Drug: 678187-11-6; Drug: 678187-12-7; Drug: 678187-13-8; Drug: 678187-14-9. chemical inhibition with antimicrotubule agents prevents mictotubule formation in vitro with purified tubulin; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 15027874 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania donovani | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 902779-03-7; Drug: 908843-57-2; Drug: 908843-58-3; Drug: 908843-61-8; Drug: 908843-63-0; Drug: 908843-68-5; Drug: 908843-70-9; Drug: 908843-73-2; Drug: 908843-74-3; Drug: 908843-75-4; Drug: 908843-76-5; Drug: 908843-77-6; Drug: 908843-78-7; Drug: 908843-79-8; Drug: 908843-80-1; Drug: 908843-81-2; Drug: 908843-82-3; Drug: 908843-84-5. chemical inhibition with antimicrotubule agents leads to cell cycle arrest in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 16675220 | |
| microtubule polymerization (GO:0046785) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania donovani | No drug identifiers listed for this gene. | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 902779-03-7; Drug: 908843-57-2; Drug: 908843-58-3; Drug: 908843-61-8; Drug: 908843-63-0; Drug: 908843-68-5; Drug: 908843-70-9; Drug: 908843-73-2; Drug: 908843-74-3; Drug: 908843-75-4; Drug: 908843-76-5; Drug: 908843-77-6; Drug: 908843-78-7; Drug: 908843-79-8; Drug: 908843-80-1; Drug: 908843-81-2; Drug: 908843-82-3; Drug: 908843-84-5. chemical inhibition with antimicrotubule agents prevents mictotubule formation in vitro with purified tubulin; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 16675220 | |
| microtubule polymerization (GO:0046785) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania tarentolae | 79195 | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 483279-44-3; Drug: 619267-15-1. chemical inhibition with antimicrotubule agents prevents mictotubule formation in vitro with purified tubulin; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 16753146 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | 449723 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 209345-04-0; Drug: 58915-19-8; Drug: 209345-05-1; Drug: 218935-77-4; Drug: 268749-50-4. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 16918078 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania infantum | 449723 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 209345-04-0; Drug: 58915-19-8; Drug: 209345-05-1; Drug: 218935-77-4; Drug: 268749-50-4. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 16918078 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | 449723 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 209345-04-0; Drug: 58915-19-8; Drug: 209345-05-1; Drug: 218935-77-4; Drug: 268749-50-4. chemical inhibition with antimicrotubule agents leads to slow growth of Leishmania sp. in cell assay; unclear as to which topoisomerase I gene(s)/enzyme(s) was/were studied. | References: | 16918078 | |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Annotated validation
No validation data for this target
Associated compounds / Druggability
Druggability index (range: 0 to 1): 0.9
Known modulators for this target
64 chemical compounds are associated with this genePredicted associations
By orthology with druggable targets
| Species | Known druggable target | Linked compounds | Reference |
|---|---|---|---|
| Trypanosoma brucei | tubulin gamma chain | Compounds | References |
By sequence similarity to non orthologous druggable targets
| Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
|---|---|---|---|---|---|---|
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Plasmodium falciparum | tubulin beta chain | 445 aa | 35.9% | 443 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Bos taurus | Tubulin | 445 aa | 34.0% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Bos taurus | Tubulin | 85 aa | 39.5% | 81 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Sus scrofa | Tubulin | 445 aa | 34.0% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
| Trypanosoma brucei | beta tubulin | 442 aa | 34.8% | 443 aa | Compounds | References |
| Bos taurus | Tubulin beta chain | 445 aa | 34.0% | 438 aa | Compounds | References |
| Leishmania major | beta tubulin | 443 aa | 35.2% | 438 aa | Compounds | References |
Obtained from network model
Ranking Plot
Putative Drugs List
Assayability
Assay information
No assay information for this target.
Reagent availability
No reagent availability information for this target.
Bibliographic References
No literature references available for this target.
If you have references for this gene, please enter them in a user comment (below) or Contact us.
User comments
No user comments are available for this gene.
Log in to add comments, or register.